Safety and Efficacy of Dalbavancin Versus Active Comparator in Adult Patients With Osteomyelitis
Status:
Terminated
Trial end date:
2017-08-31
Target enrollment:
Participant gender:
Summary
This clinical study will be a multi-center, randomized, open-label, active-controlled,
parallel-group study comparing dalbavancin to standard of care (SOC) therapy in
osteomyelitis.